Full profile
| Also known as | Pyrroloquinoline quinone, BioPQQ |
|---|---|
| Best for | Mitochondrial-support interest (cognition/fatigue, preliminary) |
| Evidence grade | Emerging — Emerging — mostly preclinical or preliminary human data |
| Studied dose range | 20 mg/day. |
| Time to effect | Studies generally run several weeks of daily use. |
| Best form | BioPQQ, the most-studied branded form. |
Evidence, honestly graded
Positive human trials exist but are single-sponsor: all run on the BioPQQ branded ingredient, funded by its developer, with no independent replication published yet. Mechanistically plausible as a mitochondrial-biogenesis cofactor, but the human evidence base is too narrow and too concentrated to grade higher.
See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.
Side effects
- Generally well tolerated
Who should avoid it or check first
- Pregnant or breastfeeding without clinician guidance (limited data)
Interactions
- Limited interaction data — discuss with a clinician if on medication
Stacks well with
- Acetyl-L-Carnitine (mechanistic mitochondrial pairing, not clinically proven as a combination)
What to look for on a label
- Specify the BioPQQ branded form — this is the material behind essentially all the human data.
References
- BioPQQ human cognition/fatigue trials. Single-sponsor (BioPQQ-funded) trials report positive effects on cognition and fatigue measures; no independent replication published to date. Educational, not a product claim.
Primary citations for some entries above are still being compiled; those without a linked identifier are editorial summaries of the wider literature.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
See how PQQ compares on grade, dose, and goal in the Evidence Explorer.